Tsvetalina Tankova

Publication Activity (10 Years)

Years Active: 2022-2022
Publications (10 Years): 4

Top Topics

Metastatic Breast Cancer

Glycemic Control

Cross Sectional

Health Insurance

Top Venues

International journal of environmental research and public health

This page only lists publications with an associated author ORCID identifier.

Publications

Melanie Jane Davies, Vanita R Aroda, Billy S Collins, Robert A Gabbay, Jennifer Green, Nisa M Maruthur, Sylvia E Rosas, Stephano Del Prato, Chantal Mathieu, Geltrude Mingrone, Ellen Burgess, Tsvetalina Tankova, Apostolos Tsapas, John B Buse
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes care 45 (11) (2022)
Melanie Jane Davies, Vanita R Aroda, Billy S Collins, Robert A Gabbay, Jennifer Green, Nisa M Maruthur, Sylvia E Rosas, Stephano Del Prato, Chantal Mathieu, Geltrude Mingrone, Ellen Burgess, Tsvetalina Tankova, Apostolos Tsapas, John B Buse
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 65 (12) (2022)
Dimitrios V Diamantis, Kalliopi Karatzi, Paris Kantaras, Stavros Liatis, Violeta M Iotova, Yulia Bazdraska, Tsvetalina Tankova, Greet Cardon, Katja Wikström, Imre Rurik, Emese Antal, Alelí M Ayala-Marín, Natalia Giménez Legarre, Konstantinos Makrilakis, Yannis Manios
Prevalence and Socioeconomic Correlates of Adult Obesity in Europe: The Feel4Diabetes Study. International journal of environmental research and public health 19 (19) (2022)
Tsvetalina Tankova, Elżbieta Senkus, Maria Beloyartseva, Simona Borštnar, Doina Catrinoiu, Mona Frolova, Alinta Hegmane, Andrej Janež, Mladen Krnić, Zoltan Lengyel, Yiola Marcou, Laura Mazilu, Bela Mrinakova, Ruth Percik, Katarina Petrakova, Gábor Rubovszky, Margarita Tokar, Eduard Vrdoljak
Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer. Cancers 14 (7) (2022)